266 related articles for article (PubMed ID: 31447303)
1. Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.
Mitchell KG; Farooqi A; Ludmir EB; Corsini EM; Zhang J; Sepesi B; Vaporciyan AA; Swisher SG; Heymach JV; Zhang J; Gomez DR; Antonoff MB
Clin Lung Cancer; 2020 Jan; 21(1):37-46.e7. PubMed ID: 31447303
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
3. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
Gomez DR; Tang C; Zhang J; Blumenschein GR; Hernandez M; Lee JJ; Ye R; Palma DA; Louie AV; Camidge DR; Doebele RC; Skoulidis F; Gaspar LE; Welsh JW; Gibbons DL; Karam JA; Kavanagh BD; Tsao AS; Sepesi B; Swisher SG; Heymach JV
J Clin Oncol; 2019 Jun; 37(18):1558-1565. PubMed ID: 31067138
[TBL] [Abstract][Full Text] [Related]
4. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
[TBL] [Abstract][Full Text] [Related]
5. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.
Arrieta O; Barrón F; Maldonado F; Cabrera L; Corona-Cruz JF; Blake M; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; García O; Arén O; De la Garza J
Lung Cancer; 2019 Apr; 130():67-75. PubMed ID: 30885354
[TBL] [Abstract][Full Text] [Related]
6. Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study.
Chen Y; Wang Y; Yang Z; Hu M; Lu J; Zhang Y; Qian F; Zhang B; Wang S; Wang K; Zhang W; Han B
Thorac Cancer; 2022 Mar; 13(5):732-741. PubMed ID: 35060346
[TBL] [Abstract][Full Text] [Related]
7. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
J Cancer Res Clin Oncol; 2020 Jan; 146(1):197-203. PubMed ID: 31599340
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer.
Mitchell KG; Farooqi A; Ludmir EB; Corsini EM; Sepesi B; Gomez DR; Antonoff MB;
J Thorac Cardiovasc Surg; 2021 Apr; 161(4):1497-1504.e2. PubMed ID: 32331820
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
[TBL] [Abstract][Full Text] [Related]
10. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
[TBL] [Abstract][Full Text] [Related]
11. Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).
Elamin YY; Gomez DR; Antonoff MB; Robichaux JP; Tran H; Shorter MK; Bohac JM; Negrao MV; Le X; Rinsurogkawong W; Lewis J; Lacerda L; Roarty EB; Swisher SG; Roth JA; Zhang J; Papadimitrakopoulou V; Heymach JV
Clin Lung Cancer; 2019 Jan; 20(1):43-47. PubMed ID: 30343004
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and survival after 18F-fluorodeoxyglucose positron emission tomography/computed tomography-guided local consolidation therapy for oligometastatic non-small cell lung cancer: a two-center propensity score-matched analysis.
Song YQ; Wang N; Qiao Y; He L; Li X; Zhang XF; Yang QK; Wang RZ; He R; Wang CY; Ren YW; Li G; Wang TL
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1021-1031. PubMed ID: 31980929
[TBL] [Abstract][Full Text] [Related]
13. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer.
Parikh RB; Cronin AM; Kozono DE; Oxnard GR; Mak RH; Jackman DM; Lo PC; Baldini EH; Johnson BE; Chen AB
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):880-7. PubMed ID: 24867533
[TBL] [Abstract][Full Text] [Related]
14. Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC.
Farooqi A; Ludmir EB; Mitchell KG; Antonoff MB; Tang C; Lee P; Chang J; Elamin Y; Gomez DR; Gandhi SJ
Radiother Oncol; 2021 Oct; 163():114-118. PubMed ID: 34419505
[TBL] [Abstract][Full Text] [Related]
15. Resection of the Primary Tumor and Survival in Patients with Single-Site Synchronous Oligometastatic Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Database.
Rodriguez-Quintero JH; Jindani R; Kamel MK; Zhu R; Vimolratana M; Chudgar NP; Stiles BM
J Am Coll Surg; 2024 Jun; 238(6):1122-1136. PubMed ID: 38334285
[TBL] [Abstract][Full Text] [Related]
16. Operation and Chemotherapy: Prognostic Factors for Lung Cancer With One Synchronous Metastasis.
Toffart AC; Duruisseaux M; Brichon PY; Pirvu A; Villa J; Selek L; Guillem P; Dumas I; Ferrer L; Levra MG; Moro-Sibilot D
Ann Thorac Surg; 2018 Mar; 105(3):957-965. PubMed ID: 29397931
[TBL] [Abstract][Full Text] [Related]
17. Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450).
De Ruysscher D; Wanders R; Hendriks LE; van Baardwijk A; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Dingemans AC
J Thorac Oncol; 2018 Dec; 13(12):1958-1961. PubMed ID: 30253974
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer.
Uhlig J; Case MD; Blasberg JD; Boffa DJ; Chiang A; Gettinger SN; Kim HS
JAMA Netw Open; 2019 Aug; 2(8):e199702. PubMed ID: 31433481
[TBL] [Abstract][Full Text] [Related]
19. Perioperative and oncologic outcomes of pulmonary resection for synchronous oligometastatic non-small cell lung cancer: Evidence for surgery in advanced disease.
Deboever N; Mitchell KG; Farooqi A; Ludmir EB; Hofstetter WL; Mehran RJ; Rajaram R; Rice DC; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Heymach JV; Gomez DR; Gandhi SJ; Antonoff MB
J Thorac Cardiovasc Surg; 2024 Jun; 167(6):1929-1935.e2. PubMed ID: 37619884
[TBL] [Abstract][Full Text] [Related]
20. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
Ashworth A; Rodrigues G; Boldt G; Palma D
Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
